Table 6.
Clinical follow-up (32 patients)
| Parameter | Value |
|---|---|
| Duration of follow-up (mo; mean [range]) | 30.3 (1.0 to 114.0) |
| Treatment | |
| none | 5 (15.6) |
| RAS blockade alone | 9 (28.1) |
| IM | 18 (56.3) |
| steroids | 11 |
| cyclophosphamide | 3 |
| cyclosporine | 2 |
| mycophenolate mofetil | 5 |
| rituximab | 4 |
| chlorambucil | 1 |
| thalidomide | 2 |
| bortezomib (Velcade) | 1 |
| Outcomea | |
| CR | 4 (12.5) |
| PR | 8 (25.0) |
| PRD | 12 (37.5) |
| Persistent hematuria (with normal creatinine and no proteinuria) | 1 (3.1) |
| ESRD | 7 (21.9) |
| Death | 5 (15.6) |
aCR: Remission of proteinuria to <500 mg/d with normal renal function; PR: Reduction in proteinuria by at least 50% and to <2 g/d with stable renal function (no more than a 20% increase in serum creatinine); PRD: Failure to meet criteria for either CR or PR but not reaching ESRD, including patients with unremitting proteinuria, or progressive chronic kidney disease.